Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features
Ahmed, N., Elwan, A., Abdelrahman, E., Embaby, A., Mohammed, A. (2022). Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features. EKB Journal Management System, 5(2), 5-15. doi: 10.21608/ajgh.2022.177155.1021
Nabila H Ahmed; Amira Elwan; Essam Adel Abdelrahman; Ahmed Embaby; Ahmed S Mohammed. "Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features". EKB Journal Management System, 5, 2, 2022, 5-15. doi: 10.21608/ajgh.2022.177155.1021
Ahmed, N., Elwan, A., Abdelrahman, E., Embaby, A., Mohammed, A. (2022). 'Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features', EKB Journal Management System, 5(2), pp. 5-15. doi: 10.21608/ajgh.2022.177155.1021
Ahmed, N., Elwan, A., Abdelrahman, E., Embaby, A., Mohammed, A. Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features. EKB Journal Management System, 2022; 5(2): 5-15. doi: 10.21608/ajgh.2022.177155.1021

Hepatocellular Carcinoma Post Direct Anti Hepatitis C Viral Agents; Clinical Features

African Journal of Gastroenterology and Hepatology
Volume 5, Issue 2, October 2022, Page 5-15  XML PDF (374.72 K)
Document Type: Original Clinical
DOI: 10.21608/ajgh.2022.177155.1021
View on SCiNiTO View on SCiNiTO
Authors
Nabila H Ahmed email orcid 1; Amira Elwan2; Essam Adel Abdelrahman3; Ahmed Embabyorcid 4; Ahmed S Mohammed5
1department of tropical medicine, faculty of medicine, zagazig university, Zagazig, Egypt
2Clinical Oncology Department, Zagazig University, Zagazig, Egypt
3Internal Medicine Department, Zagazig University, Zagazig, Egypt
4Internal Medicine Department, faculty of Medicine, Zagazig university, Egypt
5Tropical Medicine Department, Faculty of Medicine, Zagazig University,Zagazig, Egypt.
Abstract
Background:
Direct Anti Hepatitis C Viral Agents (DAAs) were introduced for Hepatitis C Virus (HCV) infection management, which resulted in high sustained virological response (SVR) in many countries and a low failure rate. However, hepatocellular carcinoma (HCC) post DAAs therapy is controversial; few studies related aggressive pattern HCC to DAAs. Therefore, we aimed to study the hepatocellular carcinoma relation to direct anti-hepatitis C viral drugs.
Patients and Methods: This observational case-control study included 67 adults Egyptian HCC patients associated with HCV diagnosed at the Zagazig University Hospitals, who were divided into two groups according to DAAs treatment.
Results:
HCC is more common in male patients (77.6%) of all studied cases, and those are treated by DAAs (62.7%). The median age of HCC post-DAA was 63(48-83), while 58 (45-75) in HCC patients without DAA, with no significant difference p= 0.053. HCC presented in the non-DAAs treated group, mainly decompensating by hematemesis (HM) (32%). While in the post-DAAs group, HCC was significantly diagnosed primarily with abdominal pain at 31%. There is no significant difference as regards the liver status with frequent liver cirrhosis in both groups, 14(56%) and 32(76.2%). 
Conclusion: DAAs therapy of HCV added no additional risk for hepatocellular carcinoma.
Keywords
Liver cirrhosis; HCV; Direct Antiviral Drugs; hepatocellular carcinoma; focal lesion
Supplementary Files
Statistics
Article View: 276
PDF Download: 220